Literature DB >> 25379057

Testosterone, HDL and cardiovascular risk in men: the jury is still out.

Katya B Rubinow1, Stephanie T Page2.   

Abstract

"Even when reductions in HDL-cholesterol are observed as a consequence of androgen therapy, the implications for cardiovascular risk modification remain highly uncertain."

Entities:  

Keywords:  HDL; androgens; cardiovascular disease; cholesterol; testosterone

Year:  2012        PMID： 25379057      PMCID： PMC4219622          DOI： 10.2217/clp.12.38

Source DB:  PubMed          Journal:  Clin Lipidol        ISSN： 1758-4302


  20 in total

Review 1.  Androgen abuse in athletes: detection and consequences.

Authors:  Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2010-02-05       Impact factor: 5.958

Review 2.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

Authors:  W E Boden
Journal:  Am J Cardiol       Date:  2000-12-21       Impact factor: 2.778

3.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 4.  Cardiovascular issues in hypogonadism and testosterone therapy.

Authors:  Ridwan Shabsigh; Mark Katz; Grace Yan; Nawras Makhsida
Journal:  Am J Cardiol       Date:  2005-12-19       Impact factor: 2.778

Review 5.  High density lipoprotein: it's not just about lipid transport anymore.

Authors:  Scott M Gordon; Susanna Hofmann; David S Askew; W Sean Davidson
Journal:  Trends Endocrinol Metab       Date:  2010-11-08       Impact factor: 12.015

6.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

Review 7.  Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Authors:  Sadeka Shahani; Milena Braga-Basaria; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

8.  High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered.

Authors:  K E Friedl; C J Hannan; R E Jones; S R Plymate
Journal:  Metabolism       Date:  1990-01       Impact factor: 8.694

9.  Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men.

Authors:  C J Bagatell; R H Knopp; J E Rivier; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

10.  Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.

Authors:  Katya B Rubinow; Tomas Vaisar; Chongren Tang; Alvin M Matsumoto; Jay W Heinecke; Stephanie T Page
Journal:  J Lipid Res       Date:  2012-04-13       Impact factor: 5.922
View more
  2 in total

1.  An update on testosterone, HDL and cardiovascular risk in men.

Authors:  Arthi Thirumalai; Katya B Rubinow; Stephanie T Page
Journal:  Clin Lipidol       Date:  2015

2.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Authors:  Arthi Thirumalai; Jonas Ceponis; John K Amory; Ronald Swerdloff; Vijaya Surampudi; Peter Y Liu; William J Bremner; Eric Harvey; Diana L Blithe; Min S Lee; Laura Hull; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.